Go Pro
NASDAQ:POAI

Predictive Oncology Q1 2025 Earnings Report

Predictive Oncology logo
$11.35 -0.15 (-1.26%)
As of 09/24/2026

Predictive Oncology EPS Results

Actual EPS
-$4.80
Consensus EPS
-$1.35
Beat/Miss
Missed by -$3.45
One Year Ago EPS
N/A

Predictive Oncology Revenue Results

Actual Revenue
$0.11 million
Expected Revenue
$1.50 million
Beat/Miss
Missed by -$1.39 million
YoY Revenue Growth
N/A

Predictive Oncology Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 15, 2025
Conference Call Time
7:00AM ET

Predictive Oncology Earnings Headlines

Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
Predictive Oncology Regains Nasdaq Compliance
See More Predictive Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Predictive Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Predictive Oncology and other key companies, straight to your email.

About Predictive Oncology

Predictive Oncology (NASDAQ:POAI) (NASDAQ: POAI) is a biotechnology company focused on using artificial intelligence and tumor biology to support cancer drug discovery and personalized medicine. The company combines machine learning with biological data to help identify potential therapies and predict how individual tumors may respond to treatment.

Its technology platform, known as PEDAL, is designed to analyze tumor samples, drug-response data and other biological information. Predictive Oncology also maintains access to a large tumor sample and data repository through its operating businesses, supporting the development and evaluation of oncology therapies for pharmaceutical and biotechnology companies.

The company has historically expanded its capabilities through businesses including Helomics, which provides tumor profiling and drug-response testing, and TumorGenesis, which focuses on developing three-dimensional tumor models for research. Predictive Oncology was formerly known as Skyline Medical and adopted its current name as it shifted its strategic focus toward artificial intelligence-driven oncology research.

View Predictive Oncology Profile